The stock of Theravance Biopharma Inc (NASDAQ:TBPH) hit a new 52-week high and has $41.11 target or 5.00% above today’s $39.15 share price. The 8 months bullish chart indicates low risk for the $2.15 billion company. The 1-year high was reported on Apr, 20 by Barchart.com. If the $41.11 price target is reached, the company will be worth $107.50M more. About 349,370 shares traded or 51.79% up from the average. Theravance Biopharma Inc (NASDAQ:TBPH) has risen 28.20% since September 13, 2016 and is uptrending. It has outperformed by 18.27% the S&P500.
Among 2 analysts covering Paladin Energy Ltd. (TSE:PDN), 0 have Buy rating, 1 Sell and 1 Hold. Therefore 0 are positive. Paladin Energy Ltd. had 8 analyst reports since August 31, 2015 according to SRatingsIntel. TD Securities maintained Paladin Energy Ltd (TSE:PDN) on Friday, July 22 with “Hold” rating. The firm has “Hold” rating given on Thursday, January 19 by TD Securities. TD Securities maintained Paladin Energy Ltd (TSE:PDN) on Wednesday, January 11 with “Hold” rating. See Paladin Energy Ltd (TSE:PDN) latest ratings:
19/01/2017 Broker: TD Securities Rating: Hold New Target: $0.10 Maintain
11/01/2017 Broker: TD Securities Rating: Hold New Target: $0.10 Maintain
16/11/2016 Broker: TD Securities Rating: Hold Old Target: $0.20 New Target: $0.15 Target Down
Theravance Biopharma, Inc. is a biopharmaceutical company. The company has market cap of $2.15 billion. The Firm is engaged in creating medicines for patients suffering from serious illness. It currently has negative earnings. The Firm operates in the segment of discovery , development and commercialization of human therapeutics.
Among 7 analysts covering Theravance Biopharma (NASDAQ:TBPH), 6 have Buy rating, 1 Sell and 0 Hold. Therefore 86% are positive. Theravance Biopharma had 8 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was initiated by Evercore on Monday, August 29 with “Buy”. The firm has “Underperform” rating by Robert W. Baird given on Wednesday, October 12. The firm earned “Buy” rating on Wednesday, December 21 by Needham. The stock of Theravance Biopharma Inc (NASDAQ:TBPH) has “Overweight” rating given on Thursday, November 3 by Piper Jaffray. Robert W. Baird maintained Theravance Biopharma Inc (NASDAQ:TBPH) rating on Wednesday, August 12. Robert W. Baird has “Neutral” rating and $14 target. Guggenheim initiated Theravance Biopharma Inc (NASDAQ:TBPH) rating on Monday, June 20. Guggenheim has “Buy” rating and $30 target. The firm earned “Outperform” rating on Thursday, May 12 by Leerink Swann.
Investors sentiment increased to 1.73 in 2016 Q4. Its up 0.02, from 1.71 in 2016Q3. It improved, as 20 investors sold Theravance Biopharma Inc shares while 13 reduced holdings. 19 funds opened positions while 38 raised stakes. 31.87 million shares or 27.84% more from 24.93 million shares in 2016Q3 were reported. Citigroup Inc, New York-based fund reported 18,585 shares. Hsbc Hldgs Public Llc invested 0% in Theravance Biopharma Inc (NASDAQ:TBPH). Ubs Asset Management Americas Inc stated it has 6,719 shares. Baupost Grp Ltd Liability Co Ma owns 9.27M shares. Balyasny Asset Lc holds 182,365 shares or 0.03% of its portfolio. The California-based California State Teachers Retirement has invested 0.01% in Theravance Biopharma Inc (NASDAQ:TBPH). 21,510 were accumulated by Sg Americas Ltd Llc. Geode Cap Mgmt Lc stated it has 312,103 shares. Creative Planning has invested 0% in Theravance Biopharma Inc (NASDAQ:TBPH). Legal And General Gp Inc Public Ltd Company, a United Kingdom-based fund reported 14,082 shares. Nationwide Fund Advisors has 24,465 shares. First Advsrs Ltd Partnership reported 39,755 shares stake. Franklin Resource Incorporated owns 0.01% invested in Theravance Biopharma Inc (NASDAQ:TBPH) for 379,400 shares. Fmr Lc stated it has 0.02% in Theravance Biopharma Inc (NASDAQ:TBPH). Vanguard Gp holds 0.01% or 2.96 million shares.
Analysts await Theravance Biopharma Inc (NASDAQ:TBPH) to report earnings on May, 8. They expect $-1.14 earnings per share, down 3.64% or $0.04 from last year’s $-1.1 per share. After $-1.36 actual earnings per share reported by Theravance Biopharma Inc for the previous quarter, Wall Street now forecasts -16.18% EPS growth.
Since March 3, 2017, it had 0 buys, and 2 selling transactions for $1.30 million activity. 14,000 shares valued at $440,975 were sold by HAUMANN BRETT K on Monday, March 6. $854,772 worth of Theravance Biopharma Inc (NASDAQ:TBPH) was sold by Shafer Bradford J on Friday, March 3.
Paladin Energy Ltd is a uranium production company. The company has market cap of $188.41 million. The Firm is engaged in the development and operation of uranium mines in Africa together with exploration and evaluation activities in Africa, Australia and Canada. It currently has negative earnings. The Company’s divisions include Exploration, Namibia and Malawi.
It closed at $0.11 lastly. It is down 31.25% since September 13, 2016 and is downtrending. It has underperformed by 41.18% the S&P500.
